Dupixent was approved for treating COPD with raised blood eosinophils in the EU in July 2024. Dupixent was also approved for the COPD indication in China last week. Sanofi’s stock has gained 16.0% so ...

Regeneron (REGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...

The FDA has approved Dupixent as an add-on maintenance treatment for adults with poorly controlled COPD and high counts of ...

The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.

The FDA has approved Dupixent (dupilumab) as an add-on therapy for adults with poorly controlled COPD, especially those with ...

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

Barclays analyst Carter Gould maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,220.00.

PureTech Health has obtained approval from the US Food and Drug Administration (FDA) for KarXT to treat schizophrenia in ...

Modalis Therapeutics has been awarded a rare paediatric disease designation by the US Food and Drug Administration (FDA) for ...

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, ...

The retrospective study presented at ESMO 2024 involved about 2,400 patients with stage 3 or 4 non-small cell lung cancer.

The man charged with attempting to assassinate Donald Trump after allegedly positioning himself with a rifle outside one of the former president's Florida golf courses on Sept. 15 pleaded not ...